Cg Oncology Inc stock is traded at $64.80, with a volume of 931,810. It is down -4.30% in the last 24 hours and down -5.69% over the past month. CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Previous Close:
$67.71
Open:
$67.34
24h Volume:
931,810
Relative Volume:
0.97
Market Cap:
$5.74B
Revenue:
$5.07M
Net Income/Loss:
-$186.75M
P/E Ratio:
-
EPS:
-$2.34
Net Cash Flow:
-$160.43M
1W Performance:
+2.10%
1M Performance:
-5.69%
6M Performance:
-3.54%
1Y Performance:
+70.71%
1-Day Range:
$64.16$67.34
1-Week Range:
$61.01$67.88
52-Week Range:
$35.80$80.97
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology IncSector
HealthcareIndustry
BiotechnologyPhone
(949) 409-3700Address
3000 PEGASUS PARK DRIVE, DALLAS, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS